FDA warns those with respiratory risk factors about the use of gabapentin, pregabalin

December 20, 2019 The US Food and Drug Administration (FDA) has issued a warning that serious breathing difficulties may occur i...

December 20, 2019

The US Food and Drug Administration (FDA) has issued a warning that serious breathing difficulties may occur in people who have respiratory risk factors and take gabapentin (Neurontin, Gralise, Horizant) or pregabalin (Lyrica, Lyrica CR).

These risk factors include taking drugs that depress the central nervous system, such as opioids; and conditions that reduce lung function, such as chronic obstructive pulmonary disease (COPD). Elderly individuals are also at higher risk.

The FDA will require new warnings on packaging for gabapentin and pregabalin drugs. If you are taking these medications and have concerns, please contact your medical provider. Seek medical attention immediately if you or someone you are caring for experiences respiratory problems.

Read the FDA warning.

The Restless Legs Syndrome Foundation is the leading organization for science-based education and patient services for people suffering from restless legs syndrome (RLS). It is also the only organization with a dedicated research grant program to advance promising research leading to new treatments and a cure. Our goals are simple: increase awareness of RLS, improve treatments, and, through research, find a cure.

You Might Also Like

0 comments

Flickr Images